November 06, 2017

Not intended for U.S. and UK Media

Bayer submits application for marketing approval of rivaroxaban for patients with coronary or peripheral artery disease to European Medicines Agency

The rivaroxaban vascular dose, 2.5 mg twice daily plus aspirin 100 mg once daily, demonstrated a 24% reduction in the combined risk of stroke, cardiovascular death and heart attack (1) / The application for marketing approval is based on the COMPASS study / If approved, the rivaroxaban vascular dose, 2.5 mg twice daily plus aspirin low dose once daily, will be the only non-vitamin K antagonist oral anticoagulant (NOAC) indicated for this patient population
Berlin, November 6, 2017 - Bayer has submitted an application to the European
Medicines Agency (EMA) for the marketing authorization of the vascular dose of
its Factor Xa inhibitor rivaroxaban (Xarelto®) in combination with aspirin for
the treatment of patients with coronary artery disease (CAD) or peripheral
artery disease (PAD). The submission is based on results of the Phase III
COMPASS study, which showed that the vascular dose of rivaroxaban (2.5 mg twice
daily) plus aspirin 100 mg once daily reduced the risk of the composite outcome
of stroke, cardiovascular (CV) death and heart attack by an unprecedented 24%
(relative risk reduction) compared with aspirin 100 mg once daily alone in
patients with CAD or PAD. A filing in the US is expected by the end of the
year.

"Heart attack and stroke represent a major public health burden and new, more
effective treatment options are needed," said Dr Joerg Moeller, Member of the
Executive Committee of Bayer AG's Pharmaceutical Division and Head of
Development. "Millions of people die each year of cardiovascular disease and we
are committed to helping patients access life-saving treatment options and
maintain a good quality of life. With rivaroxaban we have a medicine that has
already helped millions of patients and we look forward to bringing this
treatment option to many more patients in the future."

It is estimated that cardiovascular disease, which includes CAD and PAD, is
responsible for some 17.7 million deaths every year, representing 31% of all
global deaths (2). Additionally, patients with cardiovascular disease have a
reduction in life expectancy of over 7 years (3). CAD and PAD are caused by
atherosclerosis, a chronic, progressive disease which is characterized by a
build-up of plaque in the arteries (4, 5). Patients with these conditions are
at risk of thrombotic events which may lead to disability, loss of limb and
loss of life (5, 6, 7) . Current treatment guidelines recommend antiplatelet
therapies such as aspirin alone; however this has been shown to be only
modestly effective (8).

As well as demonstrating a significant reduction in the combined efficacy
endpoint of major adverse cardiovascular events (MACE), the COMPASS study also
showed that the rivaroxaban vascular dose, 2.5 mg twice daily, plus aspirin 100
mg once daily resulted in a significant reduction in stroke (42%) and CV death
(22%) compared to aspirin 100 mg once daily alone. Furthermore, the combination
regimen was associated with a 20% improvement in net clinical benefit, defined
as the reduction in stroke, CV death, and heart attack balanced against the
most serious bleeding events.

Bleeding incidence rates were low, and while there was an increase in major
bleeding, notably there was no significant increase in fatal or intracranial
bleeding. Importantly, in the PAD patient population, the combination of major
adverse limb events plus all major amputations of a vascular cause were reduced
significantly. The results of the COMPASS study were presented at the European
Society of Cardiology (ESC) Congress 2017 and published simultaneously in The
New England Journal of Medicine in August 2017.

COMPASS is part of the extensive evaluation of rivaroxaban, which, by the time
of completion, will include more than 275,000 patients in clinical trials and
real-world studies. In addition to COMPASS, Bayer is investigating rivaroxaban
in other studies in the area of cardiovascular disease including VOYAGER PAD
(patients with PAD undergoing peripheral artery interventions) and COMMANDER-HF
(patients with chronic heart failure and significant CAD).

About Rivaroxaban (Xarelto®)

Rivaroxaban is the most broadly indicated non-vitamin K antagonist oral
anticoagulant (NOAC) worldwide and is marketed under the brand name Xarelto®.
Xarelto is approved for seven indications, protecting patients across more
venous and arterial thromboembolic (VAT) conditions than any other NOAC:

- The prevention of stroke and systemic embolism in adult patients with
non-valvular atrial fibrillation (AF) and one or more risk factors

- The treatment of pulmonary embolism (PE) in adults

- The treatment of deep vein thrombosis (DVT) in adults

- The prevention of recurrent PE and DVT in adults

- The prevention of venous thromboembolism (VTE) in adult patients undergoing
elective hip replacement surgery

- The prevention of VTE in adult patients undergoing elective knee replacement
surgery

- The prevention of atherothrombotic events (cardiovascular death, myocardial
infarction or stroke) after an Acute Coronary Syndrome in adult patients with
elevated cardiac biomarkers and no prior stroke or transient ischaemic attack
(TIA) when co-administered with acetylsalicylic acid (ASA) alone or with ASA
plus clopidogrel or ticlopidine

Whilst licences may differ from country to country, across all indications
Xarelto is approved in more than 130 countries.

Rivaroxaban was discovered by Bayer, and is being jointly developed with
Janssen Research & Development, LLC. Xarelto is marketed outside the U.S. by
Bayer and in the U.S. by Janssen Pharmaceuticals, Inc. (Janssen Research &
Development, LLC and Janssen Pharmaceuticals, Inc. are part of the Janssen
Pharmaceutical Companies of Johnson & Johnson).

Anticoagulant medicines are potent therapies used to prevent or treat serious
illnesses and potentially life-threatening conditions. Before initiating
treatment with anticoagulant medicines, physicians should carefully assess the
benefit and risk for the individual patient.

Responsible use of Xarelto is a very high priority for Bayer, and the company
has developed a Prescribers Guide for physicians and a Xarelto Patient Card for
patients to support best practice.


1) Eikelboom JW, Connolly S.J. et al. New Engl J Med. 2017; 377(14):1319-1330
2) Cardiovascular Diseases. World Health Organization.
www.who.int/mediacentre/factsheets/fs317/en/. Accessed October 2017
3) Bakhai A. Pharmacoeconomics 2004;22:11-18
4) Viles-Gonzalez FJ, Fuster V, Badimon JJ. European Heart Journal
2004;25:1197-1207
5) What is Atherosclerosis? U.S. Department of Health & Human Services,
National Heart Blood and Lung Institute.
www.nhlbi.nih.gov/health/health-topics/topics/atherosclerosis. Accessed October
2017
6) What Is Peripheral Artery Disease? U.S. Department of Health & Human
Services, National Heart Blood and Lung Institute.
www.nhlbi.nih.gov/health/health-topics/topics/pad. Accessed October 2017
7) What Is Coronary Heart Disease? U.S. Department of Health & Human Services,
National Heart Blood and Lung Institute.
www.nhlbi.nih.gov/health/health-topics/topics/cad. Accessed October 2017
8) Bosch J, Eikelboom JW et al. Can J Cardiol. 2017; 33(8):1027-1035

Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields
of health care and agriculture. Its products and services are designed to
benefit people and improve their quality of life. At the same time, the Group
aims to create value through innovation, growth and high earning power. Bayer
is committed to the principles of sustainable development and to its social and
ethical responsibilities as a corporate citizen. In fiscal 2016, the Group
employed around 99,600 people and had sales of EUR 34.9 billion. Capital
expenditures amounted to EUR 2.2 billion, R&D expenses to EUR 4.4 billion. For
more information, go to www.bayer.com.



Forward-looking statements

This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer management. Various known and unknown
risks, uncertainties and other factors could lead to material differences
between the actual future results, financial situation, development or
performance of the company and the estimates given here. These factors include
those discussed in Bayer's public reports which are available on the Bayer
website at www.bayer.com. The company assumes no liability whatsoever to update
these forward-looking statements or to conform them to future events or
developments.